Galectin Therapeutics (GALT) Gains Again on Takeover, NASH Trial Speculation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Galectin Therapeutics (GALT) Adds to Recent Speculative Gains
September 22, 2016 8:19 AM EDTGalectin Therapeutics (NASDAQ: GALT) adds to recent gains amid NASH stock takeover speculation following Allergen's (NYSE: AGN) recent takeover of Tobira (NASDAQ: TBRA) at a huge... More
Galectin Therapeutics (GALT) May Have Best Read-Through From Allergan's Tobira (TBRA) Deal - H.C. Wainwright's Arce
September 20, 2016 1:09 PM EDTWhile investors are flipping out about the premium Allergan (NYSE: AGN) paid for Tobira Therapeutics (NASDAQ: TBRA), H.C. Wainwright analyst Ed Arce told StreetInsider in an interview that the premium was exaggerated given the fact that the market misread Tobira's Phase 2b trial results in late July; sending the stock... More
